PMID- 19671044
OWN - NLM
STAT- MEDLINE
DCOM- 20100125
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 15
IP  - 33
DP  - 2009
TI  - Kinases as upstream regulators of the HIF system: their emerging potential as 
      anti-cancer drug targets.
PG  - 3867-77
AB  - The hypoxia-inducible factor-1 (HIF-1) is a key regulator in the mammalian 
      response to oxygen deficiency under both physiological and pathological 
      conditions such as cancer. A number of studies indicated an association between 
      tumor hypoxia, increased hypoxia-inducible factor (HIF-1alpha) levels and a poor 
      prognosis. The HIF-1alpha regulation in response to hypoxia occurs primarily on 
      the level of protein stability due to posttranslational hydroxylation. However, 
      HIFalpha-subunits also respond to various growth factors, hormones, or cytokines 
      under non-hypoxic conditions implicating the involvement of different kinase 
      pathways in their regulation thereby increasing the interest in HIF-1alpha as a 
      new drug target. Herein, we review current knowledge about 
      phosphorylation-dependent HIF-1alpha regulation, HIF-1alpha protein-protein 
      interactions and subcellular localization with emphasis on new therapeutic 
      strategies targeting the HIF pathway.
FAU - Dimova, Elitsa Y
AU  - Dimova EY
AD  - Fachbereich Chemie, Abteilung Biochemie, Universitat Kaiserslautern, Germany. 
      dimova@chemie.uni-kl.de
FAU - Michiels, Carine
AU  - Michiels C
FAU - Kietzmann, Thomas
AU  - Kietzmann T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - EC 2.7.- (Phosphotransferases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Hypoxia
MH  - Drug Delivery Systems
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
MH  - Neoplasms/*drug therapy/physiopathology
MH  - Phosphorylation/drug effects
MH  - Phosphotransferases/antagonists & inhibitors
MH  - Prognosis
MH  - Protein Processing, Post-Translational/physiology
RF  - 148
EDAT- 2009/08/13 09:00
MHDA- 2010/01/26 06:00
CRDT- 2009/08/13 09:00
PHST- 2009/06/23 00:00 [received]
PHST- 2009/06/24 00:00 [accepted]
PHST- 2009/08/13 09:00 [entrez]
PHST- 2009/08/13 09:00 [pubmed]
PHST- 2010/01/26 06:00 [medline]
AID - CPD-Elitsa Y. Dimova (Kietzman) [pii]
AID - 10.2174/138161209789649358 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2009;15(33):3867-77. doi: 10.2174/138161209789649358.